The Public Health Agency of Canada has instructed provinces to remove the old COVID-19 vaccines to prevent mix-ups with new versions that will use the same identification number. The Canadian Press
The Public Health Agency of Canada (PHAC) has instructed provinces to dispose of existing COVID-19 vaccines to prevent confusion with new formulations that will share the same drug identification number. Dr. Donald Sheppard from PHAC explained that having both old and new vaccines in circulation could make it difficult to distinguish between them, which could lead to mix-ups at pharmacies and vaccination clinics.
Health Canada is reviewing updated vaccines that will target newer strains of the virus for a fall rollout. Instead of waiting for a completely new vaccine formulation, which would have a different number and could delay approval, the agency opted to update the current vaccines. This decision is meant to expedite the process and ensure quicker availability of vaccines.
Dr. Sheppard addressed concerns from some healthcare providers about potential gaps in vaccine access during the transition period. He noted that this practice is similar to the approach taken with other vaccines, such as those for influenza. The aim is to move COVID-19 vaccinations into a routine phase, similar to the flu shots, where old formulations are phased out as new ones are introduced.
The directive to dispose of the old vaccine stocks, which were designed to combat the XBB.1.5 variant, was issued last month. This is to make way for new vaccines targeting variants like JN.1 or KP.2. While provinces like Ontario, Alberta, Saskatchewan, and Quebec are following this directive, some regions like British Columbia and Manitoba will still offer the remaining doses of the old vaccines to those who request them.
Despite the concerns about potential confusion during this transition, Dr. Sheppard reassured the public that getting vaccinated with either the current or new formulation will offer similar protection. However, the updated vaccines are expected to provide a better match against newer variants, potentially offering enhanced protection.
